12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CHF 6001: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in about 74 healthy volunteers showed that single and repeated ascending-doses of up to 2,000 µg inhaled CHF 6001 for...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >